Predictors of COVID-19 epidemics in countries of the World Health Organization African Region

Feifei Zhang, Humphrey Karamagi, Ngoy Nsenga, Miriam Nanyunja, Miriam Karinja, Seth Amanfo, Margo Chase-Topping, Giles Calder-Gerver, Miles McGibbon, Alexandra Huber, Tara Wagner-Gamble, Chuan-Guo Guo, Samuel Haynes, Alistair Morrison, Miranda Ferguson, Gordon A. Awandare, Francisca Mutapi, Zabulon Yoti, Joseph Cabore, Matshidiso R. Moeti and Mark E. J. Woolhouse

Countries of the World Health Organization (WHO) African Region have experienced a wide range of coronavirus disease 2019 (COVID-19) epidemics. This study aimed to identify predictors of the timing of the first COVID-19 case and the per capita mortality in WHO African Region countries during the first and second pandemic waves and to test for associations with the preparedness of health systems and government pandemic responses. Using a region-wide, country-based observational study, we found that the first case was detected earlier in countries with more urban populations, higher international connectivity and greater COVID-19 test capacity but later in island nations. Predictors of a high first wave per capita mortality rate included a more urban population, higher pre-pandemic international connectivity and a higher prevalence of HIV. Countries rated as better prepared and having more resilient health systems were worst affected by the disease, the imposition of restrictions or both, making any benefit of more stringent countermeasures difficult to detect. Predictors for the second wave were similar to the first. Second wave per capita mortality could be predicted from that of the first wave. The COVID-19 pandemic highlights unanticipated vulnerabilities to infectious disease in Africa that should be taken into account in future pandemic preparedness planning.

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents a continuing threat to both global health and the global economy. By early March 2021, more than 119 million cases worldwide had been reported, with more than 2.6 million deaths. Despite the implementation of unprecedented public health interventions, including social distancing, contact tracing and large-scale lockdowns of the population, the burden of the disease has continued to rise but with substantial variation among countries and regions and with countries in many regions around the world experiencing multiple waves. As of 14 March 2021, the WHO African Region had experienced two waves of infection and had reported a total of over 2.9 million cases of infection and more than 74,000 deaths. A third wave is currently in progress.

Gaining an understanding of variation in the progression of the pandemic in different countries will aid the response to future pandemics. Current evidence from high- and middle-income countries suggests that demographics (for example, percentage of the population aged 65 years or older), comorbidities, healthcare resources and stringency of response are important risk factors for COVID-19-related infections. It was suggested that Africa would be more susceptible to SARS-CoV-2-related cases and deaths given the higher prevalence of pre-existing conditions, including tuberculosis, malaria, AIDS, diabetes, undernourishment and other communicable and non-communicable comorbidities, as well as lower accessibility to healthcare. Recent work suggests that spatial connectivity might also have an important influence on the course of the pandemic in Africa. Using the data for COVID-19 cases and deaths from the WHO COVID-19 Dashboard, this study aimed to identify predictors of the timing of the first case and the per capita mortality rate in the first and second COVID-19 pandemic waves in the WHO African Region and to test for any effect of intervention measures on COVID-19-related deaths. We included, as predictors, existing indices of epidemic preparedness—COVID-19 readiness status and the more generic infectious diseases resilience index (Supplementary Table 1)—to test the expectation that countries rated as better prepared would suffer less severe outcomes. The main findings and limitations of the study are summarized in Table 1.

Results

COVID-19 epidemics in countries of the WHO African Region. On 25 February 2020, Algeria was the first country in the WHO African Region to report COVID-19 cases (Fig. 1a). Thirty-one countries reported their first cases in the 2 weeks from 12 March to 26 March 2020. Lesotho was the last of the 47 countries to report its first case, on 14 May 2020. There was no apparent relationship between the timing of the first COVID-19 case and the first death (Fig. 1a).

The 47 Member States reported a total of 29,635 COVID-19 deaths in the first wave and 44,850 deaths in the second wave.

1Usher Institute, University of Edinburgh, Edinburgh, United Kingdom. 2WHO Regional Office for Africa, Brazzaville, Republic of Congo. 3University of Nairobi Institute of Tropical and Infectious Diseases, Nairobi, Kenya. 4School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom. 5Roslin Institute and Royal (DICK) School of Veterinary Studies, University of Edinburgh, Edinburgh, United Kingdom. 6Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China. 7West African Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana. ✉ e-mail: feifei.zhang@ed.ac.uk
However, Tanzania discontinued reporting of COVID-19-related deaths from 8 May 2020, and Burundi, Eritrea and Seychelles were outliers (0.009, 0 and 0 per 100,000 population first wave mortality rates, respectively). São Tomé and Príncipe, as well as Seychelles, had missing data on the prevalence of HIV. These five countries were, therefore, excluded from the mortality rate analyses, giving a sample size of 42. Daily new deaths in the whole WHO African Region peaked on 5 August 2020 in the first wave and on 18 January 2021 in the second wave (Fig. 1b), lagging 16 and 7 d behind the peak of daily new cases in the first and second waves, respectively. The WHO African Region as a whole experienced a higher second wave peak than the first wave: 323 deaths (on 5 August 2020) and 675 (on 18 January 2021), respectively. In the first wave, the highest mortality per 100,000 population was reported from South Africa (33.3), followed by Cape Verde (17.5) and Eswatini (8.6) (Fig. 1c). In the second wave, the highest mortality per 100,000 population was also reported from South Africa (55.4), followed by Eswatini (39.8) and Botswana (17.7) (Fig. 1d). Twenty countries had higher or similar mortality rates in the second wave than in the first wave, whereas 23 countries had lower mortality rates in the second wave than in the first wave (Fig. 2).

### Predictors of the timing of the first case

We included 47 countries and 15 predictors (Supplementary Fig. 1a–k,p–s) in the Cox regression model for timing of the first case. Spearman’s correlation identified five pairs of predictors with correlation coefficients greater than 0.6 (Extended Data Fig. 1). The univariable Cox regression model identified total population size, number of international airports, volume of international air travel, COVID-19 test capacity and COVID-19 readiness status as risk factors for earlier detection of the first case and current health expenditure (percent of GDP) as protective factors (Fig. 3 and Supplementary Table 2). In the multivariable model, the percentage of urban population (hazard ratio \(HR = 1.40, 95\% \text{ confidence interval (CI)} 1.01–1.95\)), number of international airports \(HR = 1.48, 95\% \text{ CI} 1.02–2.14\), volume of international air travel \(HR = 1.52, 95\% \text{ CI} 1.10–2.11\), COVID-19 test capacity \(HR = 3.86, 95\% \text{ CI} 1.83–8.15\) and number of borders \(HR = 2.87, 95\% \text{ CI} 1.12–7.32\) were identified as risk factors for earlier detection of the first case (Fig. 3 and Supplementary Table 2).

### Predictors of per capita mortality during the first wave

We included 42 countries and 18 predictors (Supplementary Fig. 1b–s) in the generalized linear mixed models (GLMMs) for per capita mortality in the first wave. In the univariable analyses, the percentage of urban population, GDP per capita, human development index, volume of international air travel, infectious disease resilience index, prevalence of HIV and latitude were risk factors (Fig. 4 and Supplementary Table 3). The correlation between the time to first case and per capita mortality was not significant \(P=0.22\). In the multivariable GLMM, the percentage of urban population (risk ratio \(RR = 1.61, 95\% \text{ CI} 1.25–2.06\)), volume of international air travel \(RR = 1.31, 95\% \text{ CI} 1.04–1.66\) and prevalence of HIV \(RR = 1.40, 95\% \text{ CI} 1.10–1.78\) were risk factors for mortality rate in the first wave (Fig. 4 and Supplementary Table 3). Percentage of urban population was included in all models within +2-corrected Akaike information criterion (AICc) scores (Methods); volume of international air travel and HIV prevalence were included in most but not all.

None of the predictors in the best multivariable model was correlated with any of the COVID-19 testing variables (correlation coefficients < 0.6) (Extended Data Fig. 2). We then re-ran the best multivariable GLMMs with each additional testing variable (Supplementary Fig. 1u,w–x). No test variable was associated with the per capita mortality rate and reduced the AICc, and there were no changes in the RRs estimated by the best multivariable model (Extended Data Fig. 3 and Supplementary Table 3).

There was a good consistency between the stringency index and percent change of residential mobility as indicated by the Google mobility data. After controlling for temporal and random effects, the stringency index was non-linearly associated with the residential mobility \(P<0.0001\), with an effective degree of freedom of 8.66. The \(R^2\) of the model is 0.77, and the explained deviance is 77.5%.

None of the predictors in the best multivariable model was correlated with the two stringency scores (correlation coefficients < 0.6)
In this study, we identified statistical predictors of the timing of the first case and the per capita mortality rates during the first and second COVID-19 pandemic waves for countries in the WHO African Region. The percentage of urban population, number of international airports, volume of pre-pandemic international air travel, COVID-19 test capacity and number of borders were predictors of the earlier detection of the first case. The percentage of urban population, volume of pre-pandemic international air travel and prevalence of HIV were risk factors for per capita mortality rate in the first wave. Stringency and timing of government restrictions were not associated with the mortality rate, but countries with higher proportions of urban population and higher infectious disease resilience scores were at increased risk of an adverse outcome, defined as either high AUC of stringency index and/or high per capita mortality. Predictors of per capita mortality rates in the two waves were broadly consistent, and per capita mortality rate in the first wave was predictive of per capita mortality rate in the second wave.

**Discussion**

Per capita mortality during the second wave. We included 42 countries and 19 predictors (Supplementary Fig. 1b–g,j–o,r,s,v–y and Fig. 1c) in the univariable GLMM for per capita mortality in the second wave. Consistent with the results for the univariable analysis of the first wave, human development index, infectious disease resilience index, prevalence of HIV and latitude were risk factors for per capita mortality in the second wave (Extended Data Fig. 7 and Supplementary Table 5). Per capita mortality rate in the first wave was also a risk factor. Disability-adjusted life years (DALYs) per 100,000 individuals from communicable, neonatal, maternal and nutritional diseases was identified as a protective factor.
### Fig. 2 | Scatter plot of per capita mortality in the first and second waves.

Axes on log<sub>10</sub> scale with points falling on the axes denoting zero deaths. The dashed line indicates identical levels of mortality rates in two waves. Tanzania, Burundi, Eritrea and Seychelles were not shown due to incomplete data/being outliers. Note that São Tomé and Príncipe was not included in mortality rate analyses due to missing predictor data. DRC, Democratic Republic of the Congo.

### Table

| Category     | Variable                                      | Univariable | P values | Multivariable | P values |
|--------------|-----------------------------------------------|-------------|----------|---------------|----------|
| Demographics | Population, total                             | <0.001      |          |               |          |
|              | Population density (people per sq. km of land area) | 0.222       |          |               |          |
|              | Urban population (% of total population)       | 0.091       |          |               |          |
|              | Population ages 65 and older (% of total population) | 0.859       |          |               |          |
|              | Sex ratio (male/female)                       | 0.201       |          |               |          |
| Socioeconomic| GDP per capita (current US$)                  | 0.205       |          |               |          |
|              | Human development index                       | 0.199       |          |               |          |
| Travel       | Number of international airports             | 0.045       |          |               | 0.040    |
|              | Volume of international air travel           | <0.001      |          |               | 0.012    |
| Health care  | Current health expenditure (% of GDP)         | 0.004       |          |               | 0.099    |
|              | Infectious disease resilience index           | 0.170       |          |               |          |
| Readiness    | COVID-19 test capacity, yes                   | <0.001      |          |               | <0.001   |
|              | COVID-19 readiness status, adequate           | 0.024       |          |               |          |
| Geography    | Number of borders, above 0                    | 0.131       |          |               | 0.028    |
|              | Latitude                                      | 0.375       |          |               |          |

### Fig. 3 | HRs and 95% CIs for predictors of timing of the first case in univariable and multivariable Cox regression model. n = 47 countries. Error bars are shown. Statistically significant risk factors are in red; protective factors are in blue. Exact two-sided P values for the Wald test are shown for each predictor, and two-sided P values < 0.05 were considered statistically significant.
The association between laboratory capacity to test for COVID-19 cases (evaluated before the detection of COVID-19 in the WHO African Region) and earlier detection of first COVID-19 cases was expected. This result highlights the importance and urgency of ensuring adequate preparedness, especially in the earliest stages of a pandemic, noting that COVID-19 was first detected in Africa over 7 weeks after it was first detected in China. We found that countries with more international airports and a greater volume of pre-pandemic international air travel detected their first COVID-19 cases earlier, and island nations detected their first COVID-19 cases later. Flight connectivity to China was found to be a risk factor for earlier detection of COVID-19, irrespective of their preparedness status as measured by Global Health Security Index. The observed early detection of COVID-19 cases in Africa could be due to wider seeding of an epidemic before travel restrictions were imposed (as they were in all countries in our study) resulting in a larger epidemic.

A more urban population predicts both earlier detection of COVID-19 and a higher first wave mortality rate. Urban environments are recognized as risk factors for the transmission of respiratory pathogens in general. Other studies found an association between a more urban population and the number of COVID-19 cases, and that countries with higher socio-economic development, such as Belgium, United Kingdom and Italy, have higher COVID-19 mortality rates. Countries with a more urban population and greater socio-economic development might have lower COVID-19 case fatality rates (CFRs). However, our study focused on per capita mortality, as CFR is heavily influenced by COVID-19 testing capability, which is highly heterogeneous across countries.

We also found that a higher prevalence of HIV was associated with a higher mortality rate in the first pandemic wave. HIV has been associated with severe COVID-19 during the pandemic; a large population-based study in South Africa found that HIV doubled (HR = 2.14) the risk of COVID-19 mortality. A meta-analysis of 22 studies worldwide also found that HIV-positive status was associated with an increased risk of COVID-19 mortality. The underlying reasons might include a high prevalence of comorbidities in patients with HIV and severe COVID-19 and persistent immune suppression in severe COVID-19 (ref. 21). In our study, statistical models replacing HIV with other common comorbidities—tuberculosis (which is strongly correlated with HIV), chronic obstructive pulmonary disease, hypertensive heart disease and obesity—fitted the data less well, although it is possible that HIV status acts as a marker for a basket of these and other comorbidities. Alternatively, any link could be wholly or partially indirect if HIV prevalence is correlated with behavioral, lifestyle or socioeconomic variables not included in our analysis.

We found that stringency and timing of government restrictions were not associated with the mortality rate in the first pandemic wave. Some studies found that measures including internal ‘lockdown’ and rapid border closures were not associated with COVID-19 mortality, whereas others found that rapid implementation of restrictions reduced COVID-19 mortality. There is a complex cause-and-effect relationship between restrictions and mortality rate, and our results should not be interpreted as demonstrating that restrictions are ineffective, only that any effect is difficult to detect by a retrospective statistical analysis. This is expected if countries that imposed more stringent restrictions more quickly did so in response to the observed or anticipated severity of their epidemic, and if differences in stringency, at best, only mitigated the outcome.

As the response to the pandemic is likely to be damaging in its own right (for example, through negative effects on human well-being, the economy, education and work), an alternative approach is to consider stringency as an outcome variable. The preferred outcome is a low per capita mortality rate and fewer restrictions as measured by the stringency index. Taking this approach, we found that countries were more likely to achieve a good outcome if they had a less urban population and low infectious disease resilience. Infectious disease resilience is a composite index that considers multiple factors ranging across multiple domains, including political, economic, public health, medical, demographic and disease dynamics (Supplementary Table 1). It is positively correlated with GDP per capita, the human development index, volume of international
travel and prevalence of HIV, and negatively correlated with DALY rates from both communicable diseases and non-communicable diseases (Extended Data Fig. 1). This result contradicts speculation that poor countries with a low resilience would be most affected by COVID-19 (see also ref. 11). In Africa, more urbanized countries and those considered more resilient to infectious diseases suffered more from both the direct and indirect effects of the pandemic.

Similar results for the first and second waves suggest that there were no major shifts in the epidemiology of COVID-19 over the study period, implying no systematic differences in vulnerabilities to the two waves. This indicates that, regardless of the stringency and effectiveness of the government response, intrinsic differences among countries have a substantial effect on the course of national epidemics.

This study has some limitations. It is an observational study of country-level data and cannot demonstrate a direct, causal link between predictors and outcome. Effects due to unmeasured confounders might influence the results and interpretation. Statistical power is limited by sample size, so the final multivariable models include only those predictors with the strongest effects; others might have effect sizes too small to be retained in the models. Given the enormous number of combinations of predictors that could be considered, it is possible that the best fitting models were not identified. Data quality has also been raised as an issue9. Some, possibly substantial, under-ascertainment of COVID-19 deaths is likely in Africa, as elsewhere25, and could affect our findings if the degree of under-ascertainment was correlated with predictors included in our analysis. We directly addressed this issue by including in our analyses independent estimates of under-reporting of COVID-19 deaths generated by the Institute for Health Metrics and Evaluation25. These estimates range up to approximately 75% of COVID-19 deaths unreported (in Burkina Faso, Nigeria and the Democratic Republic of the Congo). The WHO definition of a COVID-19
death does not require a positive test result, but it is possible that ascertainment is influenced by testing capacity. However, our main results are robust to inclusion of indicators of testing effort in our statistical models, although we note that test volume data were not collected over exactly the same time period.

The stringency variable is a composite index of government policies, reflecting that many countries implemented measures as a package. Not all policies are expected to have equal effect, and a wide range of combinations of measures was implemented across the region. We validated the stringency index by comparison with Google mobility data. We found a strong association, indicating that the index is related to real-world behavior by at least a subset of the population. However, the association weakened over time, as has been reported elsewhere.

Our study had several strengths. We considered countries from a single WHO region; these should be more comparable in terms both of data on predictors and of COVID-19 epidemiology. We restricted our analysis to outcome variables judged to be most reliably estimated—date of first case and mortality—while correcting for under-reporting/under-ascertainment. The evident plausibility of the results of our date of first case analysis improves confidence that the predictor and outcome data are fitted for purpose.

In conclusion, we identified risk factors associated with poor direct and indirect outcomes of the first two waves of the COVID-19 pandemic in the WHO African Region countries. Our key finding is that countries that were assumed to be better prepared and better equipped to respond to the pandemic were also the most vulnerable to it. These data should be taken into account in future pandemic preparedness planning for WHO African Region countries.

Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41591-021-01491-7.

Received: 7 May 2021; Accepted: 5 August 2021; Published online: 3 September 2021

References
1. World Health Organization. Weekly epidemiological update on COVID-19. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (2021).
2. Hsiang, S. et al. The effect of large-scale anti-contagion policies on the COVID-19 pandemic. Nature 584, 262–267 (2020).
3. Salyer, S. J. et al. The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study. Lancet 397, 1265–1275 (2021).
4. Zhong, Z. et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J. Infect. 81, e16–e25 (2020).
5. Li, Y., Ma, Z., Peppelenbosch, M. P. & Pan, Q. Potential association between COVID-19 mortality and health-care resource availability. Lancet Glob. Health 8, e4890 (2020).
6. Kandel, N., Chungong, S., Omaar, A. & Xing, J. Health security capacities in the context of COVID-19 outbreak: an analysis of International Health Regulations annual report data from 182 countries. Lancet 395, 1047–1053 (2020).
7. Brauer, M., Zhao, J. T., Bennett, F. B. & Stanaway, J. D. Global access to handwashing: implications for COVID-19 control in low-Income countries. Environ. Health Perspect. 128, 57005 (2020).
8. Walker, P. G. T. et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science 369, 413–422 (2020).
9. Rice, B. L. et al. Variation in SARS-CoV-2 outbreaks across sub-Saharan Africa. Nat. Med. 27, 447–453 (2021).
10. Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020).
11. Haider, N. et al. The Global Health Security index and Joint External Evaluation score for health preparedness are not correlated with countries’ COVID-19 detection response time and mortality outcome. Epidemiol. Infect. 148, e210 (2020).
12. Lu, L., Lycett, S., Ashworth, J., Mutapi, F. & Woolhouse, M. What are SARS-CoV-2 genomes from the WHO Africa region member states telling us? BMJ Glob. Health 6, e004408 (2021).
13. Ngi, J. M. et al. Genomic analysis of SARS-CoV-2 reveals local viral evolution in Ghana. Exp. Biol. Med. (Maywood) 246, 960–970 (2021).
14. Norwegian Institute of Public Health. Urbanization and preparedness for outbreaks with high-impact respiratory pathogens. https://apps.who.int/gph/publications/thematic_papers_2020/tp_2020_4.pdf (2020).
15. Li, M. et al. Identifying novel factors associated with COVID-19 transmission and fatality using the machine learning approach. Sci. Total Environ. 764, 142810 (2020).
16. Hashim, M. J., Alsuwaidi, A. R. & Khan, G. Population risk factors for COVID-19 mortality in 93 countries. J. Epidemiol. Glob. Health 10, 204–208 (2020).
17. Chaudhry, R., Dranitsaris, G., Mubashir, T., Bartoszko, J. & Riazi, S. A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes. EClinicalMedicine 25, 100464 (2020).
18. Asfahan, S. et al. Early trends of socio-economic and health indicators influencing case fatality rate of COVID-19 pandemic. Monaldi Arch. Chest Dis. 90, https://doi.org/10.4081/monaldi.2020.1388 (2020).
19. Lawal, Y. Africa’s low COVID-19 mortality rate: a paradox? Int. J. Infect. Dis. 102, 118–122 (2021).
20. Boulle, A. et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa1198 (2020).
21. Sentongo, P. et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci. Rep. 11, 6283 (2021).
22. Leffler, C. T. et al. Association of country-wide coronavirus mortality with demographics, testing, lockdowns, and public wearing of masks. Am. J. trop. Med. Hyg. 103, 2400–2411 (2021).
23. Fountoulakis, K. N., Fountoulakis, N. K., Koupidis, S. A. & Prezerakos, P. E. Factors determining different death rates because of the COVID-19 outbreak among countries. J. Public Health (Oxf.) 42, 681–687 (2020).
24. Woolhouse, M. How to make predictions about future infectious disease risks. Philos. Trans. R. Soc. Lond. B Biol. Sci. 366, 2045–2054 (2011).
25. Institute for Health Metrics and Evaluation. Estimation of total mortality due to COVID-19. http://www.healthdata.org/special-analysis/estimation-excess-mortality-due-covid-19-and-scalars-reported-covid-19-deaths (2021).
26. Nouvellet, P. et al. Reduction in mobility and COVID-19 transmission. Nat. Commun. 12, 1090 (2021).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021
Methods

Ethics statement. Ethics approval was not required for this study as the data used in the study were at the country level, and the study is observational.

Study design and study area. We performed a region-wide, country-based observational study (Extended Data Fig. 8) that included all 47 Member States of the WHO African Region. The WHO African Region has a total population of 1,019,922,000, with the median age varying from 15.0 years in Niger to 34.6 years in Mauritius. About 50% of the population in the WHO African Region lack access to essential medicines28. Globally, 22 of the 25 countries regarded as most vulnerable to infectious diseases are in sub-Saharan Africa21.

We extracted data for daily cases and deaths for each country in the region and calculated the following three outcomes: timing of the first case and per capita mortality rates in the first and second waves. Predictors relating to demographics, socioeconomic, travel, healthcare, comorbidities, readiness and geography were extracted from the published sources. The COVID-19 mortality reported to the WHO African Region (in Algeria). We collated values of predictor variables as close to this date as possible.

Outcomes. Our first outcome—the timing of the first case—refers to the day on which the first official laboratory-confirmed COVID-19 case/cases was/were reported to the WHO (Fig. 1a), largely based on case definitions defined by the WHO38. Our other outcomes are the total deaths per 100,000 population (per capita mortality rate) during the first and second waves, adjusted for under-reporting where appropriate (see below). According to international guidelines for certificate and coding of COVID-19 as cause of death8, a death due to COVID-19 is defined for surveillance purposes as a death resulting from a clinically compatible illness, in a probable or confirmed COVID-19 case, unless there is a clear alternative cause of death that cannot be related to COVID disease (for example, trauma). There should be no period of complete recovery from COVID-19 between illness and death.

A death due to COVID-19 might not be attributed to another disease (for example, cancer) and should be counted independently of pre-existing conditions that are suspected of triggering a severe course of COVID-19.

The pandemic curve for daily new deaths for the whole WHO African Region was plotted by using 21-d kernel smoothing using the Nadaraya–Watson estimator (Fig. 1b). Kernel smoothing is a common non-parametric method for revealing trends in data curves. The Nadaraya–Watson estimator can be seen as a weighted average using kernel as weighting functions, and a higher weight was assigned to daily new deaths closer to the target date41. We chose the date with the first minimum daily new deaths (31 October 2020) as the end of the first wave and the date of the second minimum daily new deaths (14 March 2021) as the end of the second wave, and we calculated per capita mortality rate in each wave for each country.

Data on COVID-19 cases and deaths for all 47 Member States in the WHO African Region were taken from the Oxford COVID-19 Government Response Tracker (OxCGRT). Total numbers of tests per capita were collected by the Africa Centres for Disease Control and Prevention (CDC). Statistical models were fitted to evaluate the relationships among the three outcomes and predictors. We also ran a secondary analysis for the outcomes per capita mortality in the first wave and stringency index.

The first date we used for analysis was set as 1 October 2020 when the first case was reported from the WHO African Region (in Algeria). Collected values of predictor variables as close to this date as possible.

The second case was reported from the WHO African Region (in Algeria). Collected values of predictor variables as close to this date as possible.

Predictors. A set of predictors considered likely to affect the timing of the first case and the per capita mortality rate were collected and included as explanatory variables. The definition, reasons for including the predictor, time range, details of missing data and data sources are reported in Supplementary Table 1. Predictors were classified in nine categories: demographics, socioeconomic, travel, healthcare, comorbidities, readiness and geography, COVID-19 testing and interventions. Demographic and socioeconomic variables might predict both vulnerability to severe disease (for example, by age) and transmission potential (for example, urban versus rural populations)14,30. Healthcare, readiness and COVID-19 testing variables might predict the capability to detect and/or treat cases17,35. Travel and the number of shared borders are likely to affect the imported cases from neighboring countries46. Comorbidities are related to vulnerability to dying from infection14. Latitude is related to climate, which might affect transmission rates17. Data on COVID-19 testing were obtained from four sources. Testing effort was extracted from a recent report of the COVID-19 pandemic in Africa up to the end of December 2020 (ref. 14). The predictor variable was total number of tests divided by per 100,000 population. Testing policy index data were collected by OxCGRT, which records government policy on access to testing. The ordinal scores are shown in Supplementary Table 1, and we calculated days with testing policy index ≥ 2 during the first wave (25 February to 31 October 2020). Testing policy index at the start of the second wave on 1 November 2020 was used as a baseline predictor for per capita mortality in the second wave. A test data quality index up to 31 October was generated by the TIBA Pandemic Response Unit and was placed into four categories (no data, basic, satisfactory and good; Supplementary Table 1 and Fig. 1). Details of data collection are given in the TIBA COVID-19 testing policies report29. Estimated ratios of total COVID-19 mortality reported to COVID-19 mortality were obtained from the Institute for Health Metrics and Evaluation (Supplementary Table 1).12

Government response data were collected by the TIBA Pandemic Response Unit. Details of data collection are given in the TIBA COVID-19 mitigation policies report33. Mitigation responses fall into five categories and 14 subcategories (Supplementary Table 7). Normalized strictness scores were devised for each of the 14 subcategories. Based on these normalized strictness scores, the stringency index representing policies on containment and closure were calculated using a method developed by OxCGRT28, which is by averaging the normalized strictness values of subcategories, excluding all governance and socio-economic measures and surveillance and testing from public health measures.

Two variables related to the stringency index were generated: AUC of stringency index scores from 25 February to 31 October 2020 and stringency index score when cumulative mortality reached 0.1 per 100,000 population during the first wave. Alternative thresholds ranging from 0.001 to 0.2 were also explored for validation.

Google mobility data (https://www.google.com/covid19/mobility) available for 25 WHO African Region Member States were used to validate the data for the/stringing index. Details of Google mobility data are included in the TIBA COVID-19 mitigation policies report29. The resident percent change of mobility was used to validate stringency index for the following reasons: (1) the residential category has a high correlation coefficient with the other five categories of mobility; (2) the location accuracy and the understanding vary less across regions than other categories, so the comparison among countries will cause less bias; and (3) the intention of many mitigation response measures is to encourage people to stay in their residence. As of 15 November 2020, 24 of 47 WHO African countries had mobility data for the residential category. Time series plots of stringency index against residential mobility are shown in Extended Data Fig. 9. We used a generalized additive mixed model to estimate the relationships between the stringency index and index of readiness mobility over time. We fitted the residential mobility as a spline function of stringency index s(Stringency index) and a spline function of day of the year (s(day)), which was used to control for the temporal trend. The temporal relationship between residential mobility and stringency index can be different among countries, so we also introduced a spline function of country s(country, bs = ‘re’) as random intercepts and country and day of the year (country, day, bs = ‘re’) as random slopes. The model was expressed as follows.

\[
g(Y_{ij}) = s(Stringency index) + s(day) + s(country, bs = ‘re’) + s(country, day, bs = ‘re’) + e_{ij}
\]

where \(Y_{ij}\) denoted the residential mobility for the \(i\) th day in the \(j\) th country, and \(e_{ij}\) is the random noise. \(s()\) indicated penalized spline function. \(bs = ‘re’\) indicated that the basis function is a random effect structure (basis coefficients were penalized by a ridge penalty to control the degree of smoothness). We used the default parameter settings from the R package mgcv for penalized spline function.

Statistical methods. All 47 Member States were included in the model for the timing of the first case, but the number of Member States included in the model for per capita mortality in two waves depended on the completeness of the data. The epidemic curves for both daily cases and deaths in each country within the WHO African Region were plotted to evaluate the completeness of the data. The government of the United Republic of Tanzania stopped reporting COVID-19 cases/deaths from 8 May and, therefore, was excluded.

For predictors, the most recent available data were used—and no earlier than 2010. If one predictor had missing values, one column of binary indicator was added showing which country has missing data and which has not, and both the raw data and the indicator were included in the model. All predictors used had data available for at least 90% of countries.

Spearman’s rank correlation was used to test for a correlation among predictors. Predictors with a correlation coefficient greater than 0.6 were not included in the same multivariable model.

Cox proportional hazards regression models were used to determine HRs and 95% CIs for individual predictors of timing of the first case. A univariable model was fitted first. Only predictors with \(p\)-values \(<\) 0.05 before the start date were included in this analysis. Comorbidity data were excluded, as there is no prior expectation that these would be predictors. COVID-19 test capacity, COVID-19 readiness status and the number of borders entered the model as binary variables where ‘no’, ‘limited and moderate’ and ‘no border’ were set as the reference levels, respectively. For COVID-19 readiness status, we combined ‘limited’ and ‘moderate’ into a single level—‘limited and moderate’, because of the high number of countries at the ‘limited’ level (Supplementary Fig. 1). Three countries (Cape Verde, Mauritius and Seychelles) with unknown COVID-19 readiness status were also included in the ‘limited and moderate’ level. Other variables entered the model as continuous predictors.
variables, and all continuous variables were standardized before entering the model by subtracting the mean and dividing by the standard deviation. Variables with P-values less than 0.2 were considered for inclusion in a multivariable model. If multiple variables with P-values less than 0.2 were highly correlated (correlation coefficient greater than 0.6), only one variable was selected each time to enter the multivariable model. The multivariable model with the lowest AICc was taken as the best model14, but models with +2 AICc scores were also retained. We used a GLMM with a Poisson error distribution to identify predictors of per capita mortality rate in the first wave. We used the reported deaths times the ratio of total COVID-19 mortality to reported COVID-19 mortality (Supplementary Fig. 1f) as the outcome, population size as an offset and country as a random effect. The RRb and 95% CIs were calculated. Five countries (the United Republic of Tanzania having incomplete data, Burundi, Eritrea and Seychelles being clear outliers and Seychelles and São Tomé and Príncipe having missing data for HIV prevalence) were excluded (also for the multinomial logistic regression for outcome with respect to per capita mortality in the first wave and stringency). Days with testing policy index ≥2 entered the model as a binary variable (using median as the cutoff) where ‘below median’ was set as the reference level. Three countries (Guinea-Bissau, Equatorial Guinea and Comoros) with missing days with testing index were excluded in the ‘below median’ level. We treated test data quality as binary, combining no data and basic data to the lower level (reference level), and satisfactory data and good data to the higher level. Univariable models and the best multivariable model were fitted using the same approach as for the timing of the first case. We then added the two stringency scores (AUC of stringency index in Supplementary Fig. 1y and stringency index in Supplementary Fig. 1x) to the best multivariable model and checked for significantly improved model fit (lower AICc). We first estimated the correlations between the two stringency scores and the set of selected predictors in the best multivariable model, using the Spearman rank correlation test. Then, we took the best multivariable model and re-ran it by adding each stringency score separately. Again, only stringency scores with correlation coefficients less than 0.6 with the set of selected predictors were included in the multivariable model. We repeated this exercise for the three testing variables—that is, adding days with testing policy index ≥2 (Supplementary Fig. 1u), test data quality (Supplementary Fig. 1w) and tests per capita (Supplementary Fig. 1x) to the best multivariable model for per capita mortality in the first wave and asking whether the result was consistent after adjusting for COVID-19 testing.

We carried out a secondary analysis using the original set of predictors of COVID-19 mortality in the first wave to predict an outcome combining per capita mortality in the first wave and stringency index. In this analysis, countries were placed into four groups based on the medians of total per capita mortality in the first wave and of the AUC of the stringency index (high stringency/high mortality, high stringency/low mortality, low stringency/high mortality and low stringency/low mortality). Multinomial logistic regression was used to estimate the relationship between these outcomes and the set of predictors, and the ORs and 95% CIs were calculated. Univariable models and the best multivariable model were fitted using the same approach as for the first wave mortality rate. Low stringency/low mortality was set as the reference level. COVID-19 readiness status and number of borders were excluded from the model because no country in the low/low level had adequate COVID-19 readiness status, and there was no island nation in the high/high level.

For the second wave mortality rate analysis, we fitted only the univariable model using the same approach as for first wave mortality rate. We dropped predictors related to travel and readiness, given that these pre-pandemic predictors cannot represent the baseline level at the start of the second wave. We added per capita mortality in the first wave (Fig. 1c) and testing policy index on 1 November 2020 (Supplementary Fig. 1v) as two new predictors. Testing policy index on 1 November 2020 entered the model as a binary predictor where ‘below median’ was set as the reference level. AUC of stringency in the first wave (Supplementary Fig. 1y), test data quality in the first wave (Supplementary Fig. 1w) and tests per capita as of 31 December 2020 (Supplementary Fig. 1x) were considered as predictors of second wave mortality rate, respectively.

R version 3.6.3 (R Foundation for Statistical Computing) was used in all statistical analyses. R packages used for model fitting included survival, lme4, nnet and mgcv. A two-sided P value < 0.05 was regarded as statistically significant. The raw African shapfile used in the study was obtained from Data and Maps for ArcGIS (formerly Esri Data & Maps), www.arcgis.com/home/group.htm?id=2a4836c2d9f514d18bc3e59bad5a782&overview (see the permission for use in Supplementary Table 8). Further information on predictors14 is given as Supplementary Information.

Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

Data on COVID-19 cases and deaths were from the WHO COVID-19 Dashboard (https://covid19.who.int/infect). Data sources for predictors included the World Bank, the United Nations, the Rand Corporation, Our World in Data, the WHO Region Office for Africa, Data and Maps for ArcGIS (formerly Esri Data & Maps), the Institute for Health Metrics and Evaluation, the Oxford COVID-19 Government Response Tracker and the Africa CDC (links are provided in Supplementary Table 1). All data are available via figshare at https://doi.org/10.6084/m9.figshare.15022503.

Code availability

All code is available via figshare at https://doi.org/10.6084/m9.figshare.15022503.

References

27. World Health Organization. Global Health Observatory data repository: https://apps.who.int/gho/data/node.home (2020).
28. Kirigia, J. M., Sambo, H. B., Sambo, L. G. & Barry, S. P. Economic burden of dengue in the WHO African region. BMC Int. Health Hum. Rights 9, 6 (2009).
29. Moore, M., Gefeld, B. & Ogunmogbe, A. Identifying future disease hot spots: Infectious Disease Vulnerability Index. https://www.crac.org/pubs/research_reports/RR1605.html (2016).
30. World Health Organization. WHO COVID-19: Case Definitions. https://apps.who.int/iris/handle/10665/337834 (2020).
31. World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death. https://www.who.int/classifications/icd/Guidelines_Cause_of_Death_COVID-19.pdf (2020).
32. Hazelton, M. L. Kernel Smoothing. In Wiley StatsRef: Statistics Reference Online (eds Balakrishnan, N. et al.) https://doi.org/10.1002/9781118445112.stat06535 (2014).
33. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/infot (2021).
34. Hrdlitsky, O. & Komarek, A. Demographic and public health characteristics explain large part of variability in COVID-19 mortality across countries. Eur. J. Public Health 31, 12–16 (2021).
35. Okeahalam, C., Williams, V. & Otowome, K. Factors associated with COVID-19 infections and mortality in Africa: a cross-sectional study using publicly available data. BMJ Open 10, e042750 (2020).
36. Chinazzi, M. et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science 368, 395–400 (2020).
37. Tzampoglou, P. & Loukidis, D. Investigation of the importance of climatic factors in COVID-19 worldwide intensity. Int. J. Environ. Res. Public Health 17, 7730 (2020).
38. TIBA Pandemic Response Unit. COVID-19 testing report for WHO Africa Region. https://tiba-partnership.org/tiba/sites/sbsweb2.bio.ed.ac.uk/files/pdf/TIBA-PRU%20Testing%20Data%2022.10.2020.pdf (2020).
39. TIBA Pandemic Response Unit. COVID-19 mitigation policies by governments and changes in behaviour across WHO Africa Region. https://tiba-partnership.org/tiba/sites/sbsweb2.bio.ed.ac.uk/files/pdf/COVID-19%20mitigation%20policies%20by%20governments%20and%20changes%20in%20behaviour%20across%20WHO%20Africa%20Region.pdf (2020).
40. Hale, T., Webster, S., Petherick, A., Phillips, T. & Kira, B. Oxford COVID-19 Government Response Tracker. https://www.bsg.ox.ac.uk/research/research-projects/coronavirus-government-response-tracker (2020).
41. Emiliano, P. C., Vivanco, M. J. F. & de Menezes, F. S. Information criteria: how do they behave in different models? Comput. Stat. Data Anal. 69, 141–153 (2014).
42. Arsalan, M., Mubin, O., Alnajjar, F. & Aslinglawi, B. COVID-19 global risk: expectation vs. reality. Int. J. Environ. Res. Public Health 17, 5592 (2020).
43. Takahashi, T. et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 588, 315–320 (2020).
44. Peckham, H. et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat. Commun. 11, 6317 (2020).
45. Pana, T. A. et al. Country-level determinants of the severity of the first global wave of the COVID-19 pandemic: an ecological study. BMJ Open 11, e042034 (2021).
46. Mena, G. E. et al. Socioeconomic status determines COVID-19 incidence and related mortality in Santiago, Chile. Science 372, ebeg5298 (2021).
47. Azarpazhooh, M. R. et al. COVID-19 pandemic and burden of non-communicable diseases: an ecological study on data of 185 countries. J. Stroke Cerebrovasc. Dis. 29, 105089 (2020).
48. Bakewell, J. R., Awan, N., Islam, M. M. & Moulavi, M. O. Healthcare capacity, health expenditure, and civil society as predictors of COVID-19 case fatalities: a global analysis. Front. Public Health 8, 547 (2020).
49. Vanlommel, K., Coo, A. & de Soysa, I. Health-system equity, egalitarian democracy and COVID-19 outcomes: an empirical analysis. Scand. J. Public Health 49, 104–113 (2021).
50. Torero, W. et al. Predictors of COVID-19 incidence in hospitalized COVID-19 patients: a systematic review and meta-analysis. J. Med. Virol. 92, 1875–1883 (2020).
51. Tamuzi, J. L. et al. Implications of COVID-19 in high burden countries for HIV/TB: a systematic review of evidence. BMC Infect. Dis. 20, 744 (2020).
52. Sanyaolu, A. et al. Comorbidity and its impact on patients with COVID-19. *SN Compr. Clin. Med.* [https://doi.org/10.1007/s42399-020-00363-4](https://doi.org/10.1007/s42399-020-00363-4) (2020).

53. Rahman, M. et al. A global analysis on the effect of temperature, socio-economic and environmental factors on the spread and mortality rate of the COVID-19 pandemic. *Environ. Dev. Sustain.* [https://doi.org/10.1007/s10668-020-01028-x](https://doi.org/10.1007/s10668-020-01028-x) (2020).

**Acknowledgements**

Funding support is acknowledged from the Darwin Trust of Edinburgh, received by F.Z., and the National Institute for Health Research (NIHR) Global Health Research Programme (16/136/33) using UK aid from the UK Government, received by M.E.J.W., F.M. and G.A.A. The views expressed in this publication are those of the authors and are not necessarily those of the NIHR or the Department of Health and Social Care. The TIBA Pandemic Response Unit is part of the Tackling Infections to Benefit Africa partnership. We are grateful to H. Brown from the Roslin Institute, Edinburgh for statistical advice.

**Author contributions**

M.R.M., M.E.J.W., Z.Y. and F.Z. conceived the study. M.E.J.W., F.Z. and M.C.-T. contributed to the methodological design. F.Z., M.K., G.C.-G., M.M., A.H., T.W.-G., S.H., A.M. and M.F prepared the data. F.Z. and C.-G.G. were involved in data analysis. H.K., N.N., M.N., S.A., G.A.A., F.M., Z.Y., J.C. and M.R.M. verified the results. F.Z. and M.E.J.W. drafted the manuscript. All authors contributed to the interpretation of results and had final responsibility for the decision to submit for publication.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Extended data is available for this paper at [https://doi.org/10.1038/s41591-021-01491-7](https://doi.org/10.1038/s41591-021-01491-7).

Supplementary information The online version contains supplementary material available at [https://doi.org/10.1038/s41591-021-01491-7](https://doi.org/10.1038/s41591-021-01491-7).

Correspondence and requests for materials should be addressed to Feifei Zhang.

**Peer review information** *Nature Medicine* thanks Yap Boum, Charles Mgone and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Jennifer Sargent was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

**Reprints and permissions information** is available at [www.nature.com/reprints](https://www.nature.com/reprints).
Extended Data Fig. 1 | Correlation matrix for predictors in the first wave. Positive correlations are displayed in blue and negative correlations in red colour. $n = 47$ countries. Spearman’s rank correlation test was used. Colour intensity is proportional to the correlation coefficients.
Extended Data Fig. 2 | Correlation matrix for significant predictors in multivariable model for per capita mortality in the first wave and three test variables. Positive correlations are displayed in blue and negative correlations in red colour. n = 42 countries. Spearman’s rank correlation test was used. Colour intensity is proportional to the correlation coefficients.
Extended Data Fig. 3 | Risk ratios and 95% confidence intervals of three test variables for per capita mortality in the first wave in multivariable Poisson generalized linear mixed model. n = 42 countries. Error bars are shown. Statistically significant risk factors are in red. Exact two-sided P values for the Wald test are shown for each predictor, and two-sided P values < 0.05 were considered statistically significant.

| Variable | Add days with testing policy index >= 2 (AICCond27.46) P values | Add test data quality (AIC Cond27.46) P values | Add total number of tests per 100k population as of 31 Dec. 2020 (AICCond29.58) P values |
|----------|---------------------------------------------------------------|-------------------------------------------------|------------------------------------------------------------------------------------------|
| Urban population (% of total population) | <0.001 | <0.001 | <0.001 |
| Volume of international air travel | 0.024 | 0.031 | 0.018 |
| Prevalence of HIV total (% of population ages 15–49) | 0.005 | 0.005 | 0.003 |
| Days with testing policy index >= 2, above median | 0.033 | 0.646 | |
| Test data quality satisfactory to good | 0.046 | |
| Total number of tests per 100k population as of 31 Dec. 2020 | |

Risk Ratio | 0.6 | 1.0 | 2.0

Risk Ratio | 0.6 | 1.0 | 2.0

Risk Ratio | 0.6 | 1.0 | 2.0
Extended Data Fig. 4 | Correlation matrix for significant predictors in multivariable model for per capita mortality in the first wave and two stringency indices. Positive correlations are displayed in blue and negative correlations in red colour. \( n = 42 \) countries. Spearman’s rank correlation test was used. Colour intensity is proportional to the correlation coefficients.
Extended Data Fig. 5 | Risk ratios and 95% confidence intervals of two stringency indices for per capita mortality in the first wave in multivariable Poisson generalized linear mixed model. \( n = 42 \) countries. Error bars are shown. Statistically significant risk factors are in red. Exact two-sided \( P \) values for the Wald test are shown for each predictor, and two-sided \( P \) values < 0.05 were considered statistically significant.
Extended Data Fig. 6 | Odds ratios and 95% confidence intervals for outcome with respect to AUC of stringency index and mortality rate in the first wave in univariable multinomial logistic regression model. $n=42$ countries. COVID-19 readiness status and number of borders were excluded from the model because there is no country with adequate COVID-19 readiness status in the reference low/low level and no country with no border in the high/high level, and putting them in the model will generate super wide 95% CIs. Wald test was used. Relative to low/low, $P$ values for Wald test for percentage of urban population are 0.025 (high/low), 0.028 (low/high), and 0.002 (high/high); human development index is 0.020 (high/high); infectious disease resilience index are 0.037 (low/high) and 0.006 (high/high). Error bars are shown. Statistically significant risk factors are in red.
Extended Data Fig. 7 | Risk ratios and 95% confidence intervals of predictors of per capita mortality in the first wave and second wave in univariable Poisson generalized linear mixed model. \( n = 42 \) countries. Error bars are shown. Statistically significant risk factors are in red; protective factors are in blue. Exact two-sided \( P \) values for the Wald test are shown for each predictor, and two-sided \( P \) values \(< 0.05 \) were considered statistically significant. NA, not applicable. ND, not done.

| Category          | Variable                                                   | First wave |          |          | Second wave |          |          |
|-------------------|------------------------------------------------------------|------------|----------|----------|-------------|----------|----------|
| Demographics      | Population density (people per sq. km of land area)       | 0.077      | 0.384    | 0.001    | 0.704       | 0.294    | 0.613    |
|                   | Urban population (% of total population)                   |            |          |          |             | 0.306    | 0.211    |
|                   | Population ages 65 and above (% of total population)      |            |          |          |             |          |          |
| Socioeconomic     | Sex ratio (Male/Female)                                    | 0.025      | 0.340    | 0.005    | 0.011       |          |          |
|                   | GDP per capita (current US$)                               |            |          |          |             |          |          |
|                   | Human development index                                    |            |          |          |             |          |          |
| Travel            | Number of international airports                           | 0.420      | ND       | 0.420    | ND          |          |          |
|                   | Volume of international air travel                         | 0.022      | ND       | 0.022    | ND          |          |          |
| Health care       | Current health expenditure (% of GDP)                      | 0.872      | 0.738    | <0.001   | ND          | 0.041    |          |
|                   | Infectious disease resilience index                        |            |          |          |             |          |          |
| Co-morbidities    | DALY rates per 100,000 individuals from communicable, neonatal, maternal & nutritional diseases | 0.086      | ND       | 0.086    | ND          |          | 0.041    |
|                   | DALY rates per 100,000 individuals from non-communicable disease | 0.535      | 0.068    |          |             |          |          |
|                   | Prevalence of HIV, total (% of population ages 15–49)      | 0.025      | <0.001   | 0.025    | <0.001      | 0.755    | 0.703    |
| Readiness         | Diabetes prevalence (% of population ages 20–79)            | 0.531      | ND       | 0.531    | ND          |          |          |
|                   | COVID–19 test capacity, yes                                | 0.837      | ND       | 0.837    | ND          |          |          |
| Geography         | COVID–19 readiness status, adequate                        |            |          |          |             |          |          |
|                   | Number of borders, above 0                                 | 0.751      | 0.811    |          |             | 0.011    | <0.001   |
|                   | Latitude                                                    |            |          |          |             |          |          |
| First wave mortality | Per 100K population mortality rate in the first wave      | NA         | NA       |          |             |          |          |
| First wave interventions | AUC of stringency index in the first wave                  | NA         | ND       |          |             |          |          |
| First wave testing  | Testing policy on 1st November 2020, above 2               | NA         | NA       |          |             |          |          |
|                   | Test data quality in the first wave, satisfactory to good   | ND         | ND       |          |             |          |          |
|                   | Total number of tests per 100K population as of 31 Dec. 2020 | ND         | ND       |          |             |          |          |

\( P \) values for the Wald test are shown for each predictor, and two-sided \( P \) values \(< 0.05 \) were considered statistically significant. NA, not applicable. ND, not done.
Extended Data Fig. 8 | Flow diagram.
Extended Data Fig. 9 | Residential percent change from baseline and stringency index over time in 24 countries of the WHO African Region. Time range is from first countermeasure implemented in each country in response to COVID-19 up to 31 October 2020. Y1 axis represents residential percent change from baseline (Jan 3 – Feb 6, 2020) in Google mobility data (in black). Y2 axis represents stringency index calculated from government response data collected by the TIBA Pandemic Response Unit (in red, see Methods).
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

☐ □ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
☐ □ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐ ☑ The statistical test(s) used AND whether they are one- or two-sided
☐ ☑ Only common tests should be described solely by name; describe more complex techniques in the Methods section.
☐ ☑ A description of all covariates tested
☐ ☐ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐ ☑ A full description of the statistical parameters including central tendency (e.g., means) or other basic estimates (e.g., regression coefficient) AND variability (e.g., standard deviation) or associated estimates of uncertainty (e.g., confidence intervals)
☐ ☐ For null hypothesis testing, the test statistic (e.g., F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
☐ ☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☐ ☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☐ ☐ Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

R version 3.6.3 [R Foundation for Statistical Computing, Vienna, Austria, 2020]

Data analysis

The R version 3.6.3 [R Foundation for Statistical Computing, Vienna, Austria, 2020] was used in all statistical analyses. R packages used for model fitting included survival, lme4, nnet, and mgcv. All data are made available via figshare at https://doi.org/10.6084/m9.figshare.15022503.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Data on COVID-19 cases and deaths were from the WHO COVID-19 Dashboard (https://covid19.who.int/info/). Data source for predictors included the World Bank, United Nations, Rand Corporation, Our world in data, WHO Region office for Africa, Data and Maps for ArcGIS (formerly Esri Data & Maps), Institute for Health Metrics and Evaluation, the Oxford COVID-19 Government Response Tracker, and Africa CDC (links are provided in Supplementary table 1). All data are made available via figshare at https://doi.org/10.6084/m9.figshare.15022503.
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences
- Behavioural & social sciences
- Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Sample size | We focus on the variations of COVID-19 epidemics within the WHO African Region and therefore the sample is the 47 Member States within the region. The sample is sufficient according to the one predictor in five to nine events rule (van Smeden M et al 2016, Vittinghoff E et al 2007), because we have included a maximum of 6 predictors in all our multivariable models. |
| Data exclusions | All 47 Member States were included in the first case analyses. However, Tanzania discontinued reporting of COVID-19-related deaths from 8 May 2020, and Burundi, Eritrea and Seychelles were outliers (0.009, 0 and 0 per 100K population first wave mortality rates, respectively). São Tomé & Príncipe, as well as Seychelles, had missing data on the prevalence of HIV. All five countries were therefore excluded from the mortality rate analyses, giving a sample size of 42. |
| Replication | All codes were re-run by a second author and all attempts at replication were successful. |
| Randomization | Randomization is not relevant to the study because it is an observational study. |
| Blinding | Blinding is not relevant to the study because it is an observational study. |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | Methods |
|----------------------------------|---------|
| n/a | n/a |
| - Involved in the study | - Involved in the study |
| - Antibodies | - ChIP-seq |
| - Eukaryotic cell lines | - Flow cytometry |
| - Palaeontology and archaeology | - MRI-based neuroimaging |
| - Animals and other organisms | |
| - Human research participants | |
| - Clinical data | |
| - Dual use research of concern | |